Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist.

Nussbaum, Jesse C; Hussain, Azher; Ma, Bennett; Min, K Chris; Evers, Raymond; Li, Yun; Garrett, Graigory; Stoch, S Aubrey; Iwamoto, Marian

Nussbaum, Jesse C; Hussain, Azher; Ma, Bennett; Min, K Chris; Evers, Raymond; Li, Yun; Garrett, Graigory; Stoch, S Aubrey; Iwamoto, Marian.

Nussbaum JC; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Hussain A; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Ma B; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Min KC; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Evers R; Enterin, Inc, Philadelphia, Pennsylvania.
Li Y; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Garrett G; Johnson & Johnson, Janssen Pharmaceuticals, Springhouse, Pennsylvania.
Stoch SA; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Iwamoto M; MRL, Merck & Co., Inc., Kenilworth, New Jersey, USA.

Clin Pharmacol Drug Dev ; 11(1): 123-128, 2022 01.

Article en En | MEDLINE | ID: mdl-34145987

Asunto(s)

Antagonistas del Receptor Purinérgico P2X; Pirimetamina; Humanos; Pirimetamina/efectos adversos; Pirimidinas; Receptores Purinérgicos P2X3; Sulfonamidas

Palabras clave

drug-drug interactions; multidrug and toxin extrusion transporters; purinergic receptor; renal excretion

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pirimetamina / Antagonistas del Receptor Purinérgico P2X Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google